Successful Treatment with Cyclosporine of Thrombotic Thrombocytopenic Purpura Refractory to Corticosteroids and Plasma Exchange

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 2, 2011, Pages 215-217

  Honda, Kenjiro ^a   Hidaka, Sumi ^a   Kobayashi, Shuzo ^a  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; C REACTIVE PROTEIN; CHLORIDE; CREATININE; CYCLOSPORIN; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FRESH FROZEN PLASMA; GLUCOSE; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; METALLOPROTEINASE INHIBITOR; METHYLPREDNISOLONE; NAFAMSTAT MESILATE; NITROGEN; POTASSIUM; PREDNISOLONE; PROTEIN; SODIUM; UNCLASSIFIED DRUG; UREA; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BODY TEMPERATURE; BONE MARROW BIOPSY; CASE REPORT; CELL PROLIFERATION; CHLORIDE BLOOD LEVEL; CONSCIOUSNESS LEVEL; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MALAISE; MALE; MEGAKARYOCYTE; PHYSICAL EXAMINATION; PLASMAPHERESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTHROMBIN TIME; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ADULT; CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 79953038464     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00904.x     Document Type: Letter

References (6)

1. Cataland SR, Jin M, Lin S, Kraut EH, George JN, Wu HM. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008;83:911-15.
2. Nosari A, Bernuzzi P, Corneo R etal. Late response to cyclosporine in refractory thrombotic thrombocytopenic purpura. Int J Hematol 2002;76:284-6.
3. Ferrari S, Scheiflinger F, Rieger M etal. French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007;1:2815-22.
4. Peyvandi F, Lavoretano S, Palla R etal. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008;93:232-9.
5. Banno F, Kokame K, Okuda T etal. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006;107:3161-6.
6. Motto DG, Chauhan AK, Zhu G etal. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005;115:2751-61.